Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide In Polycystic Kidney Disease Study
NCT02127437Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2014
- Primary completion
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanreotide in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Glomerular filtration rate at 36 months. Started Sep 2014; status: completed.
02
Drugs
lanreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02127437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127437.